Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239131 | 1.00 | SYNJ2 (0.52) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL7092822 | 0.93 | SYNJ2 (0.58) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL7092820 | 0.93 | SYNJ2 (0.58) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL1239221 | 0.84 | SYNJ2 (0.53) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL5336720 | 0.84 | SYNJ2 (0.53) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL1238467 | 0.82 | SYNJ2 (0.46) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL1239269 | 0.82 | SYNJ2 (0.46) | SYNJ2GAAKDM4EABL1ALPL | |
| SCHEMBL14975249 | 0.82 | SYNJ2 (0.53) | SYNJ2GAAKDM4EABL1ALPL | |
| Vitamin B17 SCHEMBL22227478 | 0.81 | SYNJ2 (0.45) | SYNJ2GAAKDM4EABL1ALPL | |
| Vitamin B17 SCHEMBL20644201 | 0.81 | SYNJ2 (0.45) | SYNJ2GAAKDM4EABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956039-B2 | Use of amygdalin analogues for the treatment of psoriasis | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2011-06-07 | — | — | US | disclosed |
| US-20110028410-A9 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2011-02-03 | — | — | US | disclosed |
| EP-1847270-A1 | USE OF AMYGDALIN ANALOGUES FOR THE TREATMENT OF PSORIASIS | Universitat Politecnica de Catalunya (ES) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028410-A9 | Use of Amygdalin Analogues for the Treatment of Psoriasis | C3AR1, CCR7, C5AR1 | SYNJ2 4699/4885GAA 4148/4885KDM4E 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.